Pandemia COVID-19: impacto y reacción rápida de la Urología / COVID-19 Pandemic: Impact and rapid reaction of Urology

La pandemia COVID-19 causada por el virus SARS-CoV-2 ha ocasionado decenas de miles de muertos en España y logrado colapsar los hospitales de la red sanitaria en la Comunidad de Madrid, debido en gran parte a su particular tendencia a causar neumonías graves con necesidad de soporte ventilatorio. Este hecho ha ocasionado el colapso de nuestro centro, llegando a tener una ocupación del 130% de sus camas por enfermos COVID-19, y causando por tanto el cese absoluto de actividad del servicio de urología, la práctica desaparición de la docencia de los residentes y la incorporación de buena parte de la plantilla de urología al grupo de personal médico que atiende a estos pacientes. Para la recuperación de esta elevada cantidad de actividad suspendida será necesaria una priorización de la patología en base a criterios puramente clínicos, para la cual se proponen tablas que recogen la relevancia de cada patología dentro de cada área de la urología. Herramientas brindadas por la tecnología como la formación online o los simuladores quirúrgicos podrán ser útiles para la necesaria restitución de la formación de residentes

The COVID-19 pandemic caused by the SARS-CoV-2 virus has caused tens of thousands of deaths in Spain and has managed to breakdown the healthcare system hospitals in the Community of Madrid, largely due to its tendency to cause severe pneumonia, requiring ventilatory support. This fact has caused our center to collapse, with 130% of its beds occupied by COVID-19 patients, thus causing the absolute cessation of activity of the urology service, the practical disappearance of resident training programs, and the incorporation of a good part of the urology staff into the group of medical personnel attending these patients. In order to recover from this extraordinary level of suspended activity, we will be obliged to prioritize pathologies based on purely clinical criteria, for which tables including the relevance of each pathology within each area of urology are being proposed. Technology tools such as online training courses or surgical simulators may be convenient for the necessary reestablishment of resident education

[COVID-19 Pandemic: Impact and rapid reaction of Urology]. / Pandemia COVID-19: impacto y reacción rápida de la Urología.

The COVID-19 pandemic caused by the SARS-CoV-2 virus has caused tens of thousands of deaths in Spain and has managed to breakdown the healthcare system hospitals in the Community of Madrid, largely due to its tendency to cause severe pneumonia, requiring ventilatory support. This fact has caused our center to collapse, with 130% of its beds occupied by COVID-19 patients, thus causing the absolute cessation of activity of the urology service, the practical disappearance of resident training programs, and the incorporation of a good part of the urology staff into the group of medical personnel attending these patients. In order to recover from this extraordinary level of suspended activity, we will be obliged to prioritize pathologies based on purely clinical criteria, for which tables including the relevance of each pathology within each area of urology are being proposed. Technology tools such as online training courses or surgical simulators may be convenient for the necessary reestablishment of resident education.

[COVID-19 Pandemic: Impact and rapid reaction of Urology]. / Pandemia COVID-19: impacto y reacción rápida de la Urología.

The COVID-19 pandemic caused by the SARS-CoV-2 virus has caused tens of thousands of deaths in Spain and has managed to breakdown the healthcare system hospitals in the Community of Madrid, largely due to its tendency to cause severe pneumonia, requiring ventilatory support. This fact has caused our center to collapse, with 130% of its beds occupied by COVID-19 patients, thus causing the absolute cessation of activity of the urology service, the practical disappearance of resident training programs, and the incorporation of a good part of the urology staff into the group of medical personnel attending these patients. In order to recover from this extraordinary level of suspended activity, we will be obliged to prioritize pathologies based on purely clinical criteria, for which tables including the relevance of each pathology within each area of urology are being proposed. Technology tools such as online training courses or surgical simulators may be convenient for the necessary reestablishment of resident education.

Impacto de la pandemia COVID-19 en el servicio de urología de un centro de referencia en la Comunidad de Madrid / Impact of the COVID-19 pandemic on the urology service of a tertiary referral center in the Community of Madrid

La pandemia COVID-19 causada por el virus SARS-CoV-2 ha causado decenas de miles de muertos en España y logrado colapsar los hospitales de la red sanitaria en la Comunidad de Madrid, debido en gran parte a su particular tendencia a causar neumonías graves con necesidad de soporte ventilatorio. Este hecho ha ocasionado el colapso de nuestro centro, llegando a tener una ocupación del 130% de sus camas por enfermos COVID-19, y causando por tanto el cese absoluto de actividad del servicio de urología, la práctica desaparición de la docencia de los residentes y la incorporación de buena parte de la plantilla de urología al grupo de personal médico que atiende a estos pacientes. Para la recuperación de esta elevada cantidad de actividad suspendida será necesaria una priorización de la patología en base a criterios puramente clínicos, para la cual se proponen tablas que recogen la relevancia de cada patología dentro de cada área de la urología. Herramientas brindadas por la tecnología como la formación online o los simuladores quirúrgicos podrán ser útiles para la necesaria restitución de la formación de residentes

The COVID-19 pandemic caused by the SARS-CoV-2 virus has caused tens of thousands of deaths in Spain and has managed to breakdown the healthcare system hospitals in the Community of Madrid, largely due to its tendency to cause severe pneumonia, requiring ventilatory support. This fact has caused our center to collapse, with 130% of its beds occupied by COVID-19 patients, thus causing the absolute cessation of activity of the urology service, the practical disappearance of resident training programs, and the incorporation of a good part of the urology staff into the group of medical personnel attending these patients. In order to recover from this extraordinary level of suspended activity, we will be obliged to prioritize pathologies based on purely clinical criteria, for which tables including the relevance of each pathology within each area of urology are being proposed. Technology tools such as online training courses or surgical simulators may be convenient for the necessary reestablishment of resident education

Silymarin and dimercaptosuccinic acid ameliorate lead-induced nephrotoxicity and genotoxicity in rats.

We studied the effect of silymarin and dimercaptosuccinic acid (DMSA), a chelating agent that was administered individually or in combination against lead (Pb) toxicity in rats. Wistar rats (200 ± 20) were randomly divided into five groups. Group A served as a control. Groups B-E were exposed to 2000 ppm of lead acetate in drinking water for 8 weeks. Group B served as a positive control. Group C received silymarin (100 mg kg(-1) orally) for 8 weeks. Group D received DMSA (75 mg kg(-1) orally) once daily for the last 5 days of treatment. Group E received DMSA and silymarin as groups C and D, respectively. The effect of Pb was evaluated and accordingly the treatments on blood lead levels (BLLs), renal system, and genotoxic effects were calculated using comet assay. The BLLs were significantly increased following the exposition of lead acetate. The administration of silymarin and DMSA provided reduction in BLLs. Silymarin and DMSA provided significant protection on the genotoxic effect of Pb. The toxic effect of Pb on kidneys was also studied. Our data suggest that silymarin and DMSA improve the renal histopathological lesions.

Enfermedad linfoproliferativa postrasplante renal. Dos décadas de experiencia / Post-transplant lymphoproliferative disorders in renal transplantation: two decades of experience

Introducción: La enfermedad linfoproliferativa postrasplante (ELP) representa un grupo heterogéneo de enfermedades que se caracterizan por una proliferación de linfocitos que se presenta después del trasplante de órganos sólidos. La mayoría de los casos de ELP son de estirpe B y su desarrollo se ha asociado estrechamente con el virus de Epstein-Barr (VEB), cuya proliferación se vería favorecida por la inhibición de la función citotóxica de los linfocitos T debido a la inmunosupresión farmacológica a la que se somete a los receptores de trasplante. Se han descrito varios factores de riesgo para el desarrollo de esta entidad, como son la seronegatividad del receptor para VEB, el grado de inmunosupresión neta global, sobre todo con el uso de anticuerpos monoclonales o policlonales, el rechazo agudo y la enfermedad por citomegalovirus (CMV). Material y métodos: Hemos estudiado la incidencia de ELP y su relación con el VEB, así como su evolución y los posibles factores de riesgo en su desarrollo, en 1.176 receptores adultos de trasplante renal de cadáver realizados en nuestro hospital, entre 1988 y 2009, con un seguimiento de uno a 255 meses. Se determinó la presencia de VEB en el tejido linfoproliferativo mediante hibridación. Analizamos la incidencia de ELP en dos períodos de tiempo, 1988-1998 y 1999-2009 con 472 y 704 pacientes, respectivamente. Resultados: Un total de 28 receptores (2,38 %), 22 hombres y 6 mujeres, con una edad media de 46,5 ± 15,36 años (18-70 años) y con una evolución media postrasplante de 72,9 ± 56,3 meses (1-180 meses), desarrollaron ELP. Trece de ellos (46,4%) no presentaban ninguno de los factores de riesgo clásicos descritos. Se detectó la presencia de VEB en el tejido linfoproliferativo de 18 de los 26 pacientes estudiados (69,2%). Respecto a su estirpe histológica 25 de los 28 eran tipo B (89,2%). Diez de los 28 pacientes diagnosticados (35,7%) recibieron tratamiento con rituximab, seis de ellos fallecieron durante el seguimiento, cinco como consecuencia directa de su enfermedad. Calculada la densidad de incidencia en los dos períodos, ésta fue muy similar en ambos grupos, de 0,003922 casos/años-paciente en el período 1988-1998 y de 0,003995 casos/años-paciente en el período 1999-2009. La supervivencia global postrasplante del paciente que presentó ELP fue del 73,6% a los 5 años y del 36,9 % a los 10 años frente al 87,8% y al 75,9% del receptor libre de enfermedad (p <0,0001). Evidenciamos una supervivencia del injerto del 62,6% a los 5 años y del 27,3% a los 10 años frente al 72,4% y al 53,9% de los injertos de los receptores libres de enfermedad (p <0,0001). En nuestra serie, la supervivencia del paciente al año de presentar la enfermedad fue del 30,9%, y del 23,2% al segundo año, y para el injerto del 15,5% del 7,7%, respectivamente. Conclusiones: Concluimos que la ELP es una entidad en su mayoría de estirpe B, asociada de forma significativa con el VEB, cuya incidencia no ha variado en el tiempo y en la que en la mitad de los casos no se identifican factores de riesgo, condicionando muy mal pronóstico a pesar de los nuevos tratamientos desarrollado (AU)

Introduction: Post-transplant lymphoproliferative disease (PTLD) represents a heterogeneous group of diseases characterised by a proliferation of lymphocytes occurring after solid organ transplantation. Most cases of PTLD are B-cell and their development has been closely associated with the Epstein-Barr virus (EBV), whose proliferation is encouraged by the inhibition of the cytotoxic function of T lymphocytes due to immunosuppressive drug treatment for transplant recipients. Several risk factors have been described for the development of this disorder, such as the seronegative state of the EBV receptor, the degree of overall net immunosuppression, especially with the use of monoclonal and polyclonal antibodies, acute rejection and cytomegalovirus (CMV) disease. Material and method: We studied the incidence of PTLD and its relationship with EBV as well as its evolution and possible risk factors in 1176 adult recipients of cadaveric renal transplantation performed in our hospital between 1988 and 2009, with a follow-up of 1-255 months. The presence of EBV in the lymphoproliferative tissue was determined using in situ hybridisation. We analysed the incidence of PTLD over two time periods, 1988-1998 and 1999-2009 with 472 and 704 patients respectively. Results: A total of 28 recipients (2.38%), 22 men and 6 women with a mean age of 46.5 (15.36) years (18-70 years) with a mean post-transplant evolution of 72.9 (56.3) months (1-180 months), developed PTLD. Thirteen (46.4%) did not show any of the classic risk factors described. The presence of EBV in lymphoproliferative tissue was detected in 18 out of 26 patients studied (69.2%). In terms of histology, 25 out of 28 were type B (89.2%). Ten out of 28 patients diagnosed (35.7%) received treatment with rituximab, six died during the follow-up, five as a direct result of their illness. The incidence for the two time periods was very similar for both groups, with 0.003922 cases/year-patient in the 1988-1998 period and 0.003995 cases/year-patient in the 1999-2009 period. Overall post-transplant survival for patients with PTLD was 73.6% at 5 years and 36.9% at 10 years, versus 87.8% and 75.9% for disease-free recipients (P<.0001). We calculated a graft survival of 62.6% at 5 years and 27.3% at 10 years versus 72.4% and 53.9% for grafts in disease-free recipients (P<.0001). In our study, patient survival one year after presenting the disease was 30.9% and 23.2% at year two. For the graft, survival was 15.5% and 7.7%, respectively. Conclusions: We conclude that PTLD is a disorder that is generally type B; it is significantly associated with EBV. Its incidence has not changed over time and half of all PTLD cases had no identifiable risk factors, which led to a poor prognosis despite the development of new treatments (AU)

[Post-transplant lymphoproliferative disorders in renal transplantation: two decades of experience]. / Enfermedad linfoproliferativa postrasplante renal. Dos décadas de experiencia.

INTRODUCTION: Post-transplant lymphoproliferative disease (PTLD) represents a heterogeneous group of diseases characterised by a proliferation of lymphocytes occurring after solid organ transplantation. Most cases of PTLD are B-cell and their development has been closely associated with the Epstein-Barr virus (EBV), whose proliferation is encouraged by the inhibition of the cytotoxic function of T lymphocytes due to immunosuppressive drug treatment for transplant recipients. Several risk factors have been described for the development of this disorder, such as the seronegative state of the EBV receptor, the degree of overall net immunosuppression, especially with the use of monoclonal and polyclonal antibodies, acute rejection and cytomegalovirus (CMV) disease. MATERIAL AND METHOD: We studied the incidence of PTLD and its relationship with EBV as well as its evolution and possible risk factors in 1176 adult recipients of cadaveric renal transplantation performed in our hospital between 1988 and 2009, with a follow-up of 1-255 months. The presence of EBV in the lymphoproliferative tissue was determined using in situ hybridisation. We analysed the incidence of PTLD over two time periods, 1988-1998 and 1999-2009 with 472 and 704 patients respectively. RESULTS: A total of 28 recipients (2.38%), 22 men and 6 women with a mean age of 46.5 (15.36) years (18-70 years) with a mean post-transplant evolution of 72.9 (56.3) months (1-180 months), developed PTLD. Thirteen (46.4%) did not show any of the classic risk factors described. The presence of EBV in lymphoproliferative tissue was detected in 18 out of 26 patients studied (69.2%). In terms of histology, 25 out of 28 were type B (89.2%). Ten out of 28 patients diagnosed (35.7%) received treatment with rituximab, six died during the follow-up, five as a direct result of their illness. The incidence for the two time periods was very similar for both groups, with 0.003922 cases/year-patient in the 1988-1998 period and 0.003995 cases/year-patient in the 1999-2009 period. Overall post-transplant survival for patients with PTLD was 73.6% at 5 years and 36.9% at 10 years, versus 87.8% and 75.9% for disease-free recipients (P<.0001). We calculated a graft survival of 62.6% at 5 years and 27.3% at 10 years versus 72.4% and 53.9% for grafts in disease-free recipients (P<.0001). In our study, patient survival one year after presenting the disease was 30.9% and 23.2% at year two. For the graft, survival was 15.5% and 7.7%, respectively. CONCLUSIONS: We conclude that PTLD is a disorder that is generally type B; it is significantly associated with EBV. Its incidence has not changed over time and half of all PTLD cases had no identifiable risk factors, which led to a poor prognosis despite the development of new treatments.

Factores pronósticos en cáncer renal localizado y localmente avanzado / Prognostic factors in localised and regionally advanced renal cell carcinoma

En los últimos 10 años se han identificado diversos factores que confieren efecto pronóstico en el cáncer renal. El estadio patológico, el grado nuclear e histológico, son los más frecuentemente estudiados y los más importantes en este momento. Evaluamos esos factores y agregamos otras variables, en un intento por encontrar nuevos parámetros que pudieran ser de utilidad. Se incluyeron para el presente estudio 96 casos de cáncer de células renales no metastásico. Encontramos como se menciona por otros autores que el estadio patológico y de Furhman son los factores pronósticos más fuertes, pero la presencia de tumor palpable, dolor o pérdida de peso también tuvieron significancia estadística (AU)

In the last 10 years, several factors have been identified to confer a prognostic effect on renal cancer outcome. Pathologic stage, nuclear and histologic grade are the most frecuent studied and the most important at this moment. We evaluated those factors and introduced some others, looking for new parameters that could be useful. 96 cases of non methastatic renal cell cancer were included in our study. We found that as was mentioned by other authors pathologic and Furhman stage are the stronger prognostic factors but the presence of palpable tumor, pain and weight lost had significance too (AU)

Molecular characterization of babesia bovis strains using PCR restriction fragment length polymorphism analysis of the msa2-a/b genes.

The merozoite surface antigen-2 (msa-2) family of Babesia bovis is a group of variable genes that share conserved 5' and 3' ends and encode for membrane-anchored glycoproteins that have been postulated as vaccine candidates. In this work, we analyzed the sequences of three of these genes (msa-2a1, a2, and 2b) from two geographically distant strains and detected a certain degree of genotypic diversity that could be exploited to work out new molecular tools for the discrimination of B. bovis field samples. Here we describe a PCR restriction assay that was developed based on this observation and tested on several B. bovis strains and isolates. The results show a strain-specific band pattern in geographically distant isolates, indicating the presence of differentially located BspMI restriction sites. This approach provides a simple method for the differentiation of American B. bovis strains.

Taking advantage of the polymorphism of the MSA-2 family for Babesia bovis strain characterization.

The Merozoite Surface Antigen-2 (MSA-2) family of Babesia bovis is a group of variable genes which share conserved 5' and 3' conserved ends. These genes encode membrane anchored glycoproteins, named MSA-2a1, a2, b and c, which are immunodominant antigens located on the surface of sporozoites and merozoites. In this work, we have analyzed the sequences of the msa-2a1, a2 and 2b genes in two geographically distant strains from Mexico and Argentina and detected a certain degree of genotypic diversity that can be exploited for the development of a new molecular tool for the discrimination of B. bovis field samples. Here, we describe a PCR restriction assay based on the msa2-a1, -a2 and -2b genes of B. bovis. When field strains from Argentina, Mexico and USA were analyzed, the results showed a strain-specific band pattern indicating the presence of differentially located BspMI restriction sites. This approach provides a simple method for the genotyping/strain differentiation of B. bovis field samples.

[Encrusted prostatitis: case report and literature review]. / Prostatitis incrustante: caso clínico y revisión de la bibliografía.

We report a case of encrusted prostatitis, term which is not found in MedLine search. Alkaline encrusted cystitis was described 70 years ago and few cases have been described since that time, most of them associated with Corynebacterium infection. In fact, we find these two entities very similar, except for the organ affected. Both present irritative urinary symptoms, alkaline urine and tisular necrosis below a calcification layer. Another entity described in 1993 is encrusted pyelitis, related to patients with immunodeficiency, particularly those with renal transplantation and also associated with ureolytic bacteria. The treatment of encrusted cystitis an pyelitis may include specific antibiotics, urinary acidification and endoscopic excision of the calcified lesions.

Prostatitis incrustante: caso clínico y revisión de la bibliografía / Encrusted prostatitis: case report and literature review

Presentamos un caso clínico de prostatitis incrustante, término que no se encuentra en la búsqueda hecha en MedLine. La cistitis alcalina incrustante se describió hace 70 años y son pocos los casos descritos desde entonces, la mayoría de ellos asociados a infección por Corynebacterium1 . De hecho, consideramos que estas dos entidades son muy similares, excepto en lo que se refiere al órgano afectado. Ambas presentan síntomas urinarios causantes de irritación, orina alcalina y necrosis tisular por debajo de una capa de calcificación. Otra entidad descrita en 1993 es la pielitis incrustante, relacionada con pacientes con inmunodeficiencia, especialmente los receptores de trasplante renal y también asociada a bacterias ureolíticas. El tratamiento de la cistitis y la pielitis incrustantes puede incluir antibióticos específicos, acidificación urinaria y escisión endoscópica de las lesiones calcificadas

We report a case of encrusted prostatitis, term which is not found in MedLine search. Alkaline encrusted cystitis was described 70 years ago and few cases have been described since that time, most of them associated with Corynebacterium infection1 In fact, we find these two entities very similar, except for the organ affected. Both present irritative urinary symptoms, alkaline urine and tisular necrosis below a calcification layer. Another entity described in 1993 is encrusted pyelitis, related to patients with immunodeficiency, particularly those with renal transplantation and also associated with ureolytic bacteria. The treatment of encrusted cystitis an pyelitis may include specific antibiotics, urinary acidification and endoscopic excision of the calcified lesions

Serological evidence of Neospora caninum infections in beef bulls in six counties of the Corrientes province, Argentina.

The purpose of the present work was to identify Neospora caninum infections in beef bulls belonging to 19 herds from six counties located in the Corrientes province, Argentina. The presence of antibodies to N. caninum was evaluated in 305 serum samples of bulls (Bos taurus and Bos indicus). Age and breed were recorded. An indirect fluorescent antibody test was used to determine specific antibodies. The number of bulls with natural Neospora-infection was 15 of 305 (4.9%). No association between serologic status and breed (odds ratio (OR), 0.53; 95% CI, 0.18-1.53) was found. Neospora-infected beef bulls were identified in the present work. The bull role in bovine neosporosis and the risk of horizontal transmission for cows should be investigated.

[Mediastinal chordoma]. / Cordoma mediastínico.

We describe a patient with chordoma located in the mid-posterior mediastinum whose first clinical symptoms were respiratory. This, together with the patient's age at presentation, made this case unusual.

Numerical analysis of fatty and mycolic acid profiles of Corynebacterium urealyticum and other related corynebacteria.

The fatty and mycolic acid profiles of 52 strains of clinical origin belonging to Corynebacterium urealyticum were subjected to numerical analysis along with those of representative members of Corynebacterium ammoniagenes, Corynebacterium bovis, Corynebacterium glutamicum, Corynebacterium jèikeium, Corynebacterium minutissimum, Corynebacterium pseudodiphtheriticum, Corynebacterium pseudotuberculosis, Corynebacterium xerosis, Corynebacterium renale, Corynebacterium cystitidis, "Corynebacterium ulcerans" and one strain of the Corynebacterium F1 group. Strains were divided into eight clusters at an amalgamation distance of 7.4. Corynebacterium urealyticum appeared as an homogeneous cluster clearly distant from others, that included several members of the genus Corynebacterium, and it was characterized by its content on unsaturated mycolic acids of mainly 28 (28:1) and 30 (30:3) carbon atoms. On the basis of these results the taxonomic "status" of Corynebacterium urealyticum, a new species within the genus Corynebacterium "sensu stricto", is further justified.

Taxonomic implications of the chemical analysis of the D2 group of corynebacteria.

Whole cell acid methanolysates from corynebacteria of the D2 group were found to contain meso-diaminopimelic acid, arabinose and galactose. Among lipids of taxonomic value, saturated and unsaturated straight chain fatty acids (14 to 18 carbon atoms), tuberculostearic acid (10-methyl octadecanoic acid) and mycolic acids were present. The last compounds ranged from 26 to 36 carbon atoms, the predominant types being 28.2, 28.1, 30.3, 30.2, 32.3 and 32.2. By reverse phase thin-layer chromatography the major menaquinone was identified as MK-9(H2)-containing nine isoprene units with two additional hydrogens. Moreover, diphosphatidylglycerol, phosphatidylglycerol, phosphatidylethanolamine, phosphatidylinositol and phosphatidylinositol mannosides were detected among the phospholipids of these bacteria. Thus, on these bases, the D2 group appears to be closely related to the true corynebacteria.